Zacks Research Has Bearish Estimate for Avantor Q1 Earnings

Avantor, Inc. (NYSE:AVTR - Free Report) - Investment analysts at Zacks Research lowered their Q1 2026 EPS estimates for Avantor in a research note issued on Tuesday, December 10th. Zacks Research analyst D. Dey now forecasts that the company will post earnings per share of $0.30 for the quarter, down from their prior forecast of $0.32. The consensus estimate for Avantor's current full-year earnings is $0.98 per share. Zacks Research also issued estimates for Avantor's Q3 2026 earnings at $0.31 EPS and FY2026 earnings at $1.26 EPS.

Other research analysts also recently issued research reports about the stock. Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Barclays dropped their price objective on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Wells Fargo & Company cut their price objective on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Monday, October 28th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th. Finally, UBS Group cut their price target on Avantor from $30.00 to $29.00 and set a "buy" rating on the stock in a report on Tuesday, October 8th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Avantor presently has an average rating of "Moderate Buy" and an average target price of $27.69.

Avantor Trading Down 0.6 %

Shares of Avantor stock traded down $0.13 on Thursday, reaching $22.53. 4,309,220 shares of the company's stock were exchanged, compared to its average volume of 6,484,671. The company has a market capitalization of $15.33 billion, a P/E ratio of 49.26, a price-to-earnings-growth ratio of 2.59 and a beta of 1.29. Avantor has a 52 week low of $19.59 and a 52 week high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The firm's 50-day moving average is $22.59 and its two-hundred day moving average is $23.55.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AVTR. Hantz Financial Services Inc. raised its position in Avantor by 2.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company's stock valued at $644,000 after buying an additional 503 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Avantor by 1.8% in the second quarter. Intech Investment Management LLC now owns 29,068 shares of the company's stock valued at $616,000 after purchasing an additional 514 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Avantor by 0.3% during the second quarter. Arizona State Retirement System now owns 186,567 shares of the company's stock valued at $3,955,000 after purchasing an additional 528 shares in the last quarter. Veracity Capital LLC lifted its position in shares of Avantor by 1.0% during the third quarter. Veracity Capital LLC now owns 52,359 shares of the company's stock valued at $1,355,000 after purchasing an additional 543 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Avantor by 2.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company's stock worth $571,000 after purchasing an additional 733 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.